Stocks
ALX Oncology Holdings Inc.ALXO
NASDAQHealthcareBiotechnology$1.14
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for cancer patients, with a focus on CD47 blockade through its lead candidate evorpacept. The company is tracking investor interest due to ongoing clinical trials and data readouts in hematologic and solid tumor indications.
52W Range: $0.86-$2.66
Congressional Interest in ALX Oncology Holdings Inc. (ALXO)
No congressional trades have been disclosed for ALX Oncology Holdings Inc. (ALXO) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ALXO?
No congressional trades found for this stock.